Morgan Stanley initiated coverage on CinCor Pharma with a new price target

2/1/22 6:10:03 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Morgan Stanley initiated coverage of CinCor Pharma with a rating of Overweight and set a new price target of $27.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CINC

Date	Price Target	Rating	Analyst
12/7/2022	$22.00	Overweight	Barclays
11/29/2022		Outperform → Perform	Oppenheimer
11/29/2022	$60.00 → $22.00	Overweight → Equal-Weight	Morgan Stanley
10/28/2022	$67.00	Buy	Goldman
8/22/2022	$73.00	Overweight	Piper Sandler
2/1/2022		Outperform	Evercore ISI
2/1/2022	$30.00	Outperform	Oppenheimer
2/1/2022	$27.00	Overweight	Morgan Stanley